Exchange: NASDAQ·Updated 07:22 PM EDT
News
all
press releases
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million. Vivos Therapeutics (NASDAQ:VVOS) stockread more...
Benzinga
More News
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Vivos Therapeutics (NASDAQ:VVOS) held its second-quarter earnings conference call on Friday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data andread more...
Benzinga
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +26.19% and -5.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Zoetis (ZTS) Surpasses Q2 Earnings Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +1.63% and -0.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares increasedread more...
Benzinga
Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associatedread more...
Benzinga
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vivos Therapeutics Inc Full Year Sales Increase
(RTTNews) - Vivos Therapeutics Inc (VVOS) released Loss for full year of -$21.17 million...
Nasdaq News: Markets
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.read more...
Benzinga

Advertisement|Remove ads.